Kirkland & Ellis LLP advised Bristol Myers Squibb, while Skadden, Arps, Slate, Meagher & Flom LLP advised Mirat on the deal. Bristol Myers Squibb (NYSE: BMY)…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
